Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens

Previous studies have demonstrated that sera from patients with prostate cancer (pca) contain autoantibodies that react with tumor-associated antigens (taas). autoantibodies to cyclin b1 and fourteen other taas were detected by enzyme-linked immunosorbent assay (elisa) and western blotting in 464 sera from patients with pca,benign prostatic hyperplasia (bph),and other controls. autoantibodies to cyclin b1 were detected in 31.0% of sera from randomly selected patients with pca versus 4.8% in sera with bph. in the further analysis,31.4% of sera from pca patients at the early stage contained anti-cyclin b1 autoantibody,and even 29.4% of patients who had normal prostate-specific antigen (psa) levels in their serum samples were observed anti-cyclin b1 positive. the cumulative positive rate of autoantibodies against seven selected taas (cyclin b1,survivin,p53,dfs70/ledgfp75,rala,mdm2,and npm1) in pca reached 80.5%,significantly higher than that in normal control sera. in summary,autoantibody to cyclin b1 might be a potential biomarker for the immunodiagnosis of early stage pca,especially useful in patients with normal psa level. this study further supports the hypothesis that a customized taa array can be used for enhancing anti-taa autoantibody detection,and it may constitute a promising and powerful tool for immunodiagnosis of pca. © 2014 liping dai et al.